Dose- and sex-independent disposition of ciprofloxacin

Höffler, D; Dalhoff, A.; Gau, Wolfgang; Beermann, D.; Michl, A

doi:10.1007/bf01977496

Cited by 60 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the pharmacokinetic parameters for ceftazidime calculated by Harding and Harper (9) were similar to those that we calculated. In this study, ciprofloxacin displayed pharmacokinetic parameter values different from those found in other studies (3,5,10,14,38). The maximum concentration in plasma and the area under the concentration-time curve for ciprofloxacin for our subjects were 45 and 34% lower, respectively, than those reported previously (38).…”

Section: Resultscontrasting

confidence: 95%

“…Blood samples were obtained from the cannula inserted in the contralateral arm at 0, 10,20,30, and 45 min and 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 6, 8, and 12 h following the start of infusion of cefpirome, ceftazidime, ceftriaxone, and imipenem. For ceftriaxone, additional blood samples were obtained at 14,16,24,36, and 48 h following the start of infusion.…”

mentioning

confidence: 99%

“…For ceftriaxone, additional blood samples were obtained at 14,16,24,36, and 48 h following the start of infusion. Blood samples were collected at 0, 10,20,30,40, and 50 min and 1, 1.16, 1.33, 1.5, 2, 2.5, 3, 3.5, 4, 4. 5,6,8,12,14, and 16 h after ciprofloxacin administration.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin

Paradis

Vallée

Allard

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We compared the pharmacokinetics and the serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Fifteen healthy volunteers received 1 g of cefpirome, ceftazidime, and ceftriaxone intravenously, 500 mg of imipenem-cilastatin intravenously, and 500 mg of ciprofloxacin orally. High-performance liquid chromatographic assays were used to quantitate unchanged antibiotic in plasma and urine. Serum bactericidal activities were determined against six clinical isolates each of Staphylococcus aureus, Enterobacter cloacae, and Pseudomonas aeruginosa by using a modified microdilution method of Reller and Stratton (L. B. Reller and C. W. Stratton, J. Infect. Dis. 136:196-204, 1977). Overall, cefpirome exhibited pharmacokinetics similar to those of ceftazidime: half-life (t,/2), 1.95 h; concentration at 1 h (Clh), 47 to 49 ig/ml for both antibiotics. Ceftriaxone displayed the longest tV2 (7.65 h) and the highest Clh (137.8 iLg/ml), while we observed the shortest t1/2 (1.05 h) and the lowest Clh (19.85 Fg/ml) with imipenem. At

show abstract

Section: Resultscontrasting

confidence: 95%

mentioning

confidence: 99%

See 1 more Smart Citation

Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin

Paradis

Vallée

Allard

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Upon multiple dosing, ciprofloxacin, enoxacin and other fluoroquinolones have shown an increase in the t 1/2 and increased V d from the first dose (Chang et al, 1988;Nix and Schentag, 1988); however, this phenomenon was not observed for norfloxacin in dogs using a dosage regimen of 5 mg/ kg every 12 h for 14 days (Brown et al, 1990) nor for ciprofloxacin in other studies (Höffler et al, 1984;Drusano et al, 1986) nor in dogs (Abadía et al, 1994b). The area under the concentration time curve normalized to a 1 mg/kg dose decreased as the dose of norfloxacin increased from 5 mg/kg to 20 mg/kg in healthy dogs (Brown et al, 1990).…”

Section: Pharmacokineticsmentioning

confidence: 94%

“…The multiple dose phenomenon described by Nix and Schentag (1988) and the non-linearity of the AUC with increasing doses in dogs observed by Brown et al (1990) may reflect a decreased absorption of fluoroquinolones at higher doses, or may be the result of complicated enterohepatic recycling that may occur after repeated doses. The pharmacokinetics seems to be independent of the gender (Höffler et al, 1984) although individual fluoroquinolones may vary depending on the metabolic pathways and routes of excretion.…”

Section: Pharmacokineticsmentioning

confidence: 99%

Quinolones: a class of antimicrobial agents

Sárközy¹

2001

Vet. Med. - Czech

119

View full text Add to dashboard Cite

ABSTRACT:The fluoroquinolones are a series of synthetic antibacterial agents that are used in the treatment of a variety of bacterial infections. These agents inhibit the DNA gyrase, abolishing its activity by interfering with the DNA-rejoining reaction. The inhibition of the resealing leads to the liberation of fragments that are subsequently destroyed by the bacterial exonucleases. All fluoroquinolones accumulate within bacteria very rapidly, so that a steady-state intrabacterial concentration is obtained within a few minutes. Resistance develops slowly and is usually chromosomal and not plasmid mediated. However, development of resistance and transfer between animal and human pathogens has become a fervently argued issue among the microbiologists. Another concern regarding the use of new quinolones in the veterinary field is a possible detrimental effect on the environment. It still seems unlikely that the controlled use of veterinary quinolones will give rise to unfavorable effects on the environment.

show abstract

The Pharmacokinetics and Serum and Urine Bactericidal Activity of Ciprofloxacin

Brittain

Scully

McElrath

et al. 1985

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Ciprofloxacin is an investigational quinolone agent possessing an impressive antibacterial spectrum. Its pharmacokinetics were studied in six volunteers after 250-mg and 500-mg single oral doses, and its bactericidal activity compared to that of trimethoprim-sulfamethoxazole given to the same volunteers. Mean peak serum levels were 1.45 micrograms/mL and 2.46 micrograms/mL for 250-mg and 500-mg doses, and time to peak was 1 and 1.3 hours. The 12-hour levels were 0.12 micrograms and 0.22 microgram. Half-life (T1/2)alpha were 0.32 and 0.43 with T1/2 beta were 3.97 and 4.15 and volume of distribution (area) were 80L and 90L, respectively. Area under the concentration curve (AUC) was 5.65 h X micrograms/mL and 10.37h X micrograms/mL. Serum clearance was 23L for both doses. Approximately 49% of the 250-mg dose and 43% of the 500-mg dose was recovered in the urine. Bactericidal levels were determined against clinical isolates. Sera at 1.5 hours after the 500-mg dose averaged bactericidal levels of 1:20 or better for an Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and beta-lactamase producing Haemophilus influenzae and Branhamella catarrhalis. Urinary bactericidal levels at eight to 12 hours were greater than or equal to 1:157 for E coli, K pneumoniae, gentamicin-piperacillin resistant P aeruginosa, Staphylococcus aureus, and 1:20 for Streptococcus faecalis. Serum bactericidal levels were superior, and urine bactericidal levels were superior or equal to the bactericidal levels obtained with trimethoprim-sulfamethoxazole.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Dose- and sex-independent disposition of ciprofloxacin

Cited by 60 publications

References 8 publications

Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin

Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin

Quinolones: a class of antimicrobial agents

The Pharmacokinetics and Serum and Urine Bactericidal Activity of Ciprofloxacin

Contact Info

Product

Resources

About